0000000000529782

AUTHOR

Fahd Al-mulla

0000-0001-5409-3829

showing 4 related works from this author

Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression

2015

As part of the Halifax Project, this review brings attention to the potential effects of environmental chemicals on important molecular and cellular regulators of the cancer hallmark of evading growth suppression. Specifically, we review the mechanisms by which cancer cells escape the growth-inhibitory signals of p53, retinoblastoma protein, transforming growth factor-beta, gap junctions and contact inhibition. We discuss the effects of selected environmental chemicals on these mechanisms of growth inhibition and cross-reference the effects of these chemicals in other classical cancer hallmarks.

Cancer ResearchReviewHazardous Substanceschemistry.chemical_compoundNeoplasmsAnimalsHumansMedicinebiologyAnimalbusiness.industryMedicine (all)Retinoblastoma proteinContact inhibitionCancerEnvironmental ExposureGeneral MedicineEnvironmental exposureEvasion (ethics)medicine.diseaseCell biologychemistryHazardous SubstanceImmunologyCancer cellbiology.proteinNeoplasmSignal transductionGrowth inhibitionbusinessHumanSignal TransductionCarcinogenesis
researchProduct

Mutant K-ras2 in serum

2003

Mutant tumour derived DNA has been detected in the sera of colorectal cancer patients. We investigated if mutant serum KRAS2 was detectable preoperatively in a large group of patients with colorectal neoplasia. A prospective study of 94 patients who underwent putative curative resection for colorectal carcinoma (CRC) was performed to ascertain if serum mutant KRAS2 could be used postoperatively as a disease marker.Preoperative sera from 78 patients were analysed (group A). Sera from 94 patients were obtained three monthly for up to three years during the postoperative period (group B). Codon 12 and 13 KRAS2 mutations were analysed in matched tumour and serum samples.In the preoperative grou…

MaleLetterColorectal cancervirusesMutantDNA Mutational AnalysisBioinformaticsProto-Oncogene Proteins p21(ras)03 medical and health sciencesCollaborative group0302 clinical medicineProto-Oncogene ProteinsMedicineHumansRas2neoplasmsGene030304 developmental biologyAged0303 health sciencesbusiness.industryPoint mutationGastroenterologyDNA NeoplasmMiddle Agedmedicine.diseasePrognosis3. Good healthProto-Oncogene Proteins p21(ras)Molecular analysisCarcinoembryonic AntigenEpidemiologic Studies030220 oncology & carcinogenesisCancer researchras ProteinsFemaleNeoplasm Recurrence LocalbusinessColorectal NeoplasmsBiomarkers
researchProduct

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

2015

Goodson, William H. et al.

Cancer ResearchCarcinogenesis[SDV]Life Sciences [q-bio]METHOXYCHLOR-INDUCED ALTERATIONSReviewPharmacologyMESH: Carcinogens EnvironmentalCarcinogenic synergiesChemical mixturesNeoplasmsMESH: AnimalsMESH: NeoplasmsCarcinogenesiRisk assessmentCancerACTIVATED PROTEIN-KINASESMedicine (all)Low dose1. No povertyCumulative effectsBREAST-CANCER CELLSGeneral MedicineEnvironmental exposureMESH: CarcinogenesisBIO/10 - BIOCHIMICAEPITHELIAL-MESENCHYMAL TRANSITION3. Good health[SDV] Life Sciences [q-bio]Environmental CarcinogenesisESTROGEN-RECEPTOR-ALPHARisk assessmentHumanMESH: Environmental ExposureENDOCRINE-DISRUPTING CHEMICALSTARGETING TISSUE FACTOR[SDV.CAN]Life Sciences [q-bio]/CancerBiologyPrototypical chemical disruptorsExposure[SDV.CAN] Life Sciences [q-bio]/CancerEnvironmental healthmedicine[SDV.EE.SANT] Life Sciences [q-bio]/Ecology environment/HealthCarcinogenEnvironmental carcinogenesis[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/HealthMESH: HumansAnimalPOLYBROMINATED DIPHENYL ETHERSCancerEnvironmental Exposuremedicine.diseaseMESH: Hazardous SubstancesCarcinogens EnvironmentalMIGRATION INHIBITORY FACTORVASCULAR ENDOTHELIAL-CELLSHazardous SubstanceNeoplasmCarcinogenesis
researchProduct

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

2001

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, whi…

MaleOncologyCancer ResearchPathologyMultivariate analysisDatabases FactualSettore MED/06 - Oncologia MedicaColorectal cancerGene mutationmedicine.disease_cause0302 clinical medicineGenotypeColorectal cancer Ki-ras mutationRegistriesAged 80 and over0303 health sciencesMutationValineMiddle Aged3. Good healthKRAS Mutation Analysismedicine.anatomical_structureOncologyPresented by the Kirsten ras in-colorectal-cancer collaborative group030220 oncology & carcinogenesisFemaleColorectal NeoplasmsAdultmedicine.medical_specialtyAdolescentGenotypeoverall survivalMutation MissenseRectumcolorectal cancerDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPoint MutationK-rasCodoncolorectal cancer; K-ras; prognosis; overall survivalAgedNeoplasm StagingProportional Hazards Models030304 developmental biologybusiness.industryCancermedicine.diseaseSurvival AnalysisGenes rasMultivariate Analysisprognosisbusiness
researchProduct